Research Study: LOWER
Condition:
familial hypercholesterolemia (FH)
Study Sponsor: Aegerion Pharmaceuticals
Study Investigator: Jay Traverse, MD
Study Contact: Christine Majeski
christine.majeski@allina.com
612-863-3546
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Eligibility Criteria:

  • Adult patients (age ≥18 years) who meet one of the following two criteria:

Initiating treatment with lomitapide at the time of registry enrolment, or initiated treatment with lomitapide within 15 months prior to enrolment into the registry and after lomitapide commercial availability in the country.

  • Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures.

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!